Edition:
United Kingdom

Natco Pharma Ltd (NATP.NS)

NATP.NS on National Stock Exchange of India

502.65INR
11:28am BST
Change (% chg)

Rs-4.40 (-0.87%)
Prev Close
Rs507.05
Open
Rs515.00
Day's High
Rs516.90
Day's Low
Rs499.00
Volume
72,705
Avg. Vol
231,948
52-wk High
Rs848.30
52-wk Low
Rs480.00

Latest Key Developments (Source: Significant Developments)

India's Natco Pharma March Quarter Consol Net Profit Falls
Monday, 27 May 2019 

May 27 (Reuters) - Natco Pharma Ltd ::MARCH QUARTER CONSOL NET PROFIT 1.2 BILLION RUPEES VERSUS 3 BILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 4.56 BILLION RUPEES VERSUS 7.68 BILLION RUPEES YEAR AGO.DECLARED THIRD INTERIM DIVIDEND OF 1.25 RUPEES PER SHARE.  Full Article

Natco Pharma Gets ANDA Approval From USFDA For Bosentan Tablets
Thursday, 2 May 2019 

May 2 (Reuters) - Natco Pharma Ltd ::GOT ANDA APPROVAL FROM USFDA FOR BOSENTAN TABLETS IN STRENGTHS OF 62.5 MG AND 125 MG.  Full Article

Lupin In Alliance With Natco Pharma Gets FDA Approval For Bosentan Tablets
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Lupin Ltd ::LUPIN IN ALLIANCE WITH NATCO RECEIVES FDA APPROVAL FOR BOSENTAN TABLETS.  Full Article

India's Natco Pharma Dec Qtr Consol Net Profit Falls
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Natco Pharma Ltd ::DEC QUARTER CONSOL NET PROFIT 1.60 BILLION RUPEES VERSUS PROFIT 2.18 BILLION RUPEES YEAR AGO.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 5.57 BILLION RUPEES VERSUS 5.62 BILLION RUPEES YEAR AGO.DECLARED INTERIM DIVIDEND OF 3.50 RUPEES PER SHARE.  Full Article

Natco Pharma Launches Valsartan/Sacubitril Tablet In India
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Natco Pharma Ltd ::SAYS NATCO LAUNCHES VALSARTAN/SACUBITRIL TABLET IN INDIA.SAYS DRUG IS USED FOR CERTAIN TYPES OF HEART FAILURE.  Full Article

India's Natco Pharma Sept-Qtr Consol Profit Rises
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Natco Pharma Ltd ::SEPT QUARTER CONSOL NET PROFIT 1.83 BILLION RUPEES VERSUS PROFIT 848 MILLION RUPEES YEAR AGO.SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 5.44 BILLION RUPEES VERSUS 4.27 BILLION RUPEES YEAR AGO.NATCO PHARMA LTD - APPROVED BUY-BACK OF SHARES WORTH NOT MORE THAN 2.50 BILLION RUPEES AT 1,000 RUPEES PER SHARE.  Full Article

Natco Pharma Says Co's Mekaguda Facility Undergoing Routine U.S. FDA Inspection
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Natco Pharma Ltd ::NATCO PHARMA CLARIFIES ON NEWS ITEM ON US FDA INSPECTION AT CO'S MEKAGUDA FACILITY IN TELANGANA.CO'S MANUFACTURING FACILITIES UNDERGO AUDITS FROM REGULATORY AUTHORITIES ON A REGULAR BASIS; INSPECTION IS NOT A MATERIAL EVENT‍​.  Full Article

Natco Pharma Launches Tafnat, Tenofovir Alafenamide Tablets In India
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Natco Pharma Ltd ::SAYS NATCO LAUNCHES TAFNAT, TENOFOVIR ALAFENAMIDE TABLETS, FOR TREATMENT OF CHRONIC HEPATITIS B, IN INDIA.  Full Article

Natco Pharma says Alvogen gets approval ‍​for generic oseltamivir phosphate powder for oral suspension
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Natco Pharma Ltd :Marketing partner Alvogen gets final approval ‍​for generic equivalent to oseltamivir phosphate powder for oral suspension in U.S..  Full Article

India's Natco Pharma Sept-qtr consol profit up about 28 pct
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Natco Pharma Ltd :Sept quarter consol net profit 848 million rupees versus profit of 665 million rupees last year.Consensus forecast for Sept quarter consol net profit was 811.5 million rupees.Sept quarter consol revenue from operations 4.27 billion rupees versus 4.68 billion rupees last year.Says approved raising of funds worth up to 15 billion ‍​rupees‍​.Says approved equity participation not exceeding 75 million rupees in OMRV Hospitals Pvt.  Full Article